Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Blood (2025) 146 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2025-4074

Published: 2025

Journal Articles

First-in-human trial of GT719, a novel stem cell-derived allogeneic anti-CD19 CAR-iNKT cell therapy for relapsed/refractory B cell malignancies

Dehui Zou, Wei LIU, Yan Xu, Huimin Liu, Yi Wang, Sisi Feng, Xiaona Xu, He Zhang, Ershao Zhang, Jiang Li, Jingman Wang, Jing Hao, Ning Wang, Huiping Zheng, Yin Cheng, Jun Cui, Jingwei Sun, Yarong Liu

Blood (2025) 146 (Supplement 1): 7693.

https://doi.org/10.1182/blood-2025-7693

Published: 2025

Journal Articles

MYC-dependent permissiveness of PI3K hyperactivation renders metabolic vulnerability in R/R b-ALL

Junzhe Song, Huimin Liu, Xiaotian Ji, Kai Liu, Shiqi Luo, Yalin Kang, Ran Ding, Lars Klemm, Jianping Jin, Huilin Huang, Yuanhui Mao, He Huang, Markus Müschen, Gang Xiao

Blood (2025) 146 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2025-1475

Published: 2025

Journal Articles

Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study

Wei LIU, Yi Wang, Huimin Liu, Qi Wang, Hesong Zou, Yan Xu, Wenyang Huang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 3683.

https://doi.org/10.1182/blood-2025-3683

Published: 2025

Journal Articles

Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy

Hesong Zou, Chen Jia, Wei LIU, Huimin Liu, Yi Wang, Yan Xu, Shuhua Yi, Gang An, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2025-1938

Published: 2025

Journal Articles

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Blood (2025) 146 (Supplement 1): 2299.

https://doi.org/10.1182/blood-2025-2299

Published: 2025

Journal Articles

Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-naïve TFH-derived peripheral T-cell lymphoma

Huimin Liu, Wei LIU, Wenyang Huang, Yi Wang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 1864.

https://doi.org/10.1182/blood-2025-1864

Published: 2025

Journal Articles

Bispecific antibodies serve as a safe and effective bridging therapy prior to CD19 CAR T-cell therapy/combinational therapy of CD19 CAR-T cell and HDT/ASCT in patients with R/R DLBCL

Yi Wang, Wei LIU, Huimin Liu, Qi Wang, Weiwei Sui, Rui Lv, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 4545.

https://doi.org/10.1182/blood-2025-4545

Published: 2025

Journal Articles

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Blood (2025) 146 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2025-4015

Published: 2025

Journal Articles

Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia

Xiong Wenjie, Yuting Yan, Tingyu Wang, Weiwei Sui, Ying Yu, Tengteng Yu, Rui Lyu, Wei Liu, Huimin Liu, Gang An, Wenyang Huang, Dehui Zou, Lu-Gui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2024-198864

Published: 2024

Journal Articles

Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial

Ting Xie, Wei Liu, Wenyang Huang, Huimin Liu, Weiwei Sui, Yi Wang, Wenjie Xiong, Yan Xu, Lugui Qiu, Dehui Zou

Blood (2024) 144 (Supplement 1): 4481.

https://doi.org/10.1182/blood-2024-204363

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Wei Liu, Yi Wang, Yan Xu, Chenxing Du, Qi Wang, Tingyu Wang, Wenyang Huang, Shuaishuai Zhang, Shuhua Yi, Yuting Yan, Tengteng Yu, Weiwei Sui, Gang An, Rui Lyu, Huimin Liu, Wenjie Xiong, Mingwei Fu, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6232.

https://doi.org/10.1182/blood-2023-185669

Published: 2023

Journal Articles

PTEN Counter Balances mTORC1 and PI3K Activities to Maintain Metabolic Homeostasis of B-ALL

Huimin Liu, Junzhe Song, Mark E Robinson, Gang Xiao, Markus Müschen

Blood (2023) 142 (Supplement 1): 2780.

https://doi.org/10.1182/blood-2023-184800

Published: 2023

Journal Articles

CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study

Wei Liu, Wenyang Huang, Rui Lv, Huimin Liu, Shuhua Yi, Hong Liu, Lulu Lv, Lugui Qiu, Jianxiang Wang, Dehui Zou

Blood (2022) 140 (Supplement 1): 4598–4599.

https://doi.org/10.1182/blood-2022-167104

Published: 2022

Journal Articles

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

Wei Liu, Hesong Zou, Yan Xu, Huimin Liu, Chenxing Du, Rui Lv, Wenyang Huang, Weiwei Sui, Shuhua Yi, Lulu Lv, Lugui Qiu, Jianxiang Wang, Dehui Zou

Blood (2022) 140 (Supplement 1): 7472–7473.

https://doi.org/10.1182/blood-2022-166451

Published: 2022

Journal Articles

R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma

Shuhua Yi, Yi Wang, Yuting Yan, Jiawen Chen, Wei Liu, Tingyu Wang, Gang An, Weiwei Sui, Wenyang Huang, Xiong Wenjie, Huimin Liu, Qi Sun, Huijun Wang, Zhijian Xiao, Jianxiang Wang, Dehui Zou, Lugui Qiu

Blood (2022) 140 (Supplement 1): 6512–6513.

https://doi.org/10.1182/blood-2022-165237

Published: 2022

Journal Articles

A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma

Huimin Liu, Hesong Zou, Wei Liu, Wenyang Huang, Shuhui Deng, Rui Lv, Weiwei Sui, Yan Xu, Shuhua Yi, Tingyu Wang, Mingwei Fu, Gang An, Yaozhong Zhao, Lugui Qiu, Dehui Zou

Blood (2022) 140 (Supplement 1): 10585–10586.

https://doi.org/10.1182/blood-2022-163258

Published: 2022

Journal Articles

Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study

Ying Yu, ShuHua Yi, Xiong Wenjie, Tingyu Wang, Yuting Yan, Wei Liu, Weiwei Sui, Gang An, Yan Xu, Huimin Liu, Wenyang Huang, Dehui Zou, Lugui Qiu

Blood (2022) 140 (Supplement 1): 3587–3588.

https://doi.org/10.1182/blood-2022-162338

Published: 2022

Journal Articles

Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Wei Liu, Wenyang Huang, Ryu Lv, Shuhui Deng, MD, Shuhua Yi, MD, Huimin Liu, Lulu Lv, Lugui Qiu, MD, Dehui Zou, MD, Jianxiang Wang, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-139351

Published: 2020

Journal Articles

Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study

Shuhua Yi, MD, Jun Du, Ying Yu, Yang Jiao, Yi Wang, Huijun Wang, Tingyu Wang, Rui Lv, Wei Liu, Wenjie Xiong, PhD, Huimin Liu, Wenyang Huang, Dehui Zou, MD, Gang An, Yaozhong Zhao, Jianxiang Wang, MD, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139481

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

First-in-human trial of GT719, a novel stem cell-derived allogeneic anti-CD19 CAR-iNKT cell therapy for relapsed/refractory B cell malignancies

MYC-dependent permissiveness of PI3K hyperactivation renders metabolic vulnerability in R/R b-ALL

Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study

Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-naïve TFH-derived peripheral T-cell lymphoma

Bispecific antibodies serve as a safe and effective bridging therapy prior to CD19 CAR T-cell therapy/combinational therapy of CD19 CAR-T cell and HDT/ASCT in patients with R/R DLBCL

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia

Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

PTEN Counter Balances mTORC1 and PI3K Activities to Maintain Metabolic Homeostasis of B-ALL

CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma

A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma

Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study

Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only